Crinetics Pharmaceuticals, Inc.
CRNX
$36.05
-$1.84-4.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 158.40% | -43.59% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 158.40% | -43.59% | -- |
| Cost of Revenue | 29.39% | 46.13% | 13.99% | 42.93% | 46.04% |
| Gross Profit | -20.13% | -45.90% | -8.80% | -43.98% | -46.04% |
| SG&A Expenses | 90.56% | 101.86% | 100.67% | 70.57% | 65.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.58% | 62.57% | 56.46% | 50.69% | 51.21% |
| Operating Income | -41.08% | -62.40% | -55.96% | -51.51% | -51.21% |
| Income Before Tax | -52.16% | -69.33% | -56.15% | -44.59% | -34.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.39% | -69.33% | -56.15% | -44.59% | -34.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.39% | -69.33% | -56.15% | -44.59% | -34.11% |
| EBIT | -41.08% | -62.40% | -55.96% | -51.51% | -51.21% |
| EBITDA | -41.21% | -62.68% | -56.23% | -51.23% | -50.58% |
| EPS Basic | -46.61% | -43.94% | -31.54% | -12.26% | 1.58% |
| Normalized Basic EPS | -46.41% | -43.95% | -31.55% | -12.27% | 1.59% |
| EPS Diluted | -46.61% | -43.94% | -31.54% | -12.26% | 1.58% |
| Normalized Diluted EPS | -46.41% | -43.95% | -31.55% | -12.27% | 1.59% |
| Average Basic Shares Outstanding | 3.94% | 17.63% | 18.71% | 28.79% | 36.26% |
| Average Diluted Shares Outstanding | 3.94% | 17.63% | 18.71% | 28.79% | 36.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |